Literature DB >> 14665507

Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients.

Argyris S Michalopoulos1, Stefanos Geroulanos, Spyros D Mentzelopoulos.   

Abstract

STUDY
OBJECTIVES: To develop and prospectively validate models of independent predictors of candidemia and candidemia-related death in cardiothoracic ICU (CICU) patients.
DESIGN: (1) An initial, prospective, one-center, case-control, independent predictor-model determining study; and (2) a prospective, two-center, model-validation study.
SETTING: The initial study was performed at the 14-bed CICU of the Onassis Cardiac Surgery Center, Athens, Greece; the model-validation study was performed at the Onassis Cardiac Surgery Center CICU and the 12-bed CICU of Henry Dunant General Hospital, Athens, Greece. PATIENTS: In the initial study, 4,312 patients admitted to the Onassis Center CICU between March 1997 and October 1999 were considered for enrollment; 30 candidemic and 120 control patients (case/control ratio, 1/4) matched according to potential confounders were ultimately enrolled. In the model-validation study, 2,087 patients admitted to the Onassis and Henry Dunant CICUs between November 1999 and May 2002 were prospectively enrolled. MEASUREMENTS AND
RESULTS: Models of predictors of candidemia and associated death were constructed with stepwise logistic regression and subsequently validated. Independent candidemia predictors were ongoing invasive mechanical ventilation (IMV) > OR =10 days, hospital-acquired bacterial infection and/or bacteremia, cardiopulmonary bypass duration > 120 min, and diabetes mellitus. Model performance was as follows: sensitivity, 53.3%/57.9%; specificity, 100%/100%; positive predictive value (PPV), 100%/100%; negative predictive value (NPV), 88.9%/99.6%; and accuracy, 90.1%/99.6% (initial/model-validation study values, respectively). IMV > or =10 days and hospital-acquired bacterial infection/bacteremia were the two strongest candidemia predictors. APACHE (acute physiology and chronic health evaluation) II score > or =30 at candidemia onset independently predicted candidemia-related death with 80.0%/85.7% sensitivity, 80%/75% specificity, 66.7%/66.7% PPV, 88.9%/88.9% NPV, and 80.0%/78.9% accuracy (initial/model-validation study values, respectively).
CONCLUSIONS: We provided a set of easily determinable independent predictors of the occurrence of candidemia in CICU patients. Our results provide a rationale for implementing preventive measures in the form of independent predictor control, and initiating antifungal prophylaxis in high-risk CICU patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665507     DOI: 10.1378/chest.124.6.2244

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  Risk factors for candidemia in critically ill infants: a matched case-control study.

Authors:  Kristina N Feja; Fann Wu; Kevin Roberts; Maureen Loughrey; Mirjana Nesin; Elaine Larson; Phyllis Della-Latta; Janet Haas; Jeannie Cimiotti; Lisa Saiman
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

2.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Risk factors and predictors of mortality of candidaemia among critically ill patients: role of antifungal prophylaxis in its development and in selection of non-albicans species.

Authors:  Matthaios Papadimitriou-Olivgeris; Anastasia Spiliopoulou; Fotini Fligou; Iris Spiliopoulou; Lora Tanaseskou; Georgios Karpetas; Markos Marangos; Evangelos D Anastassiou; Myrto Christofidou
Journal:  Infection       Date:  2017-07-29       Impact factor: 3.553

4.  Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship.

Authors:  Sibylle C Mellinghoff; Pia Hartmann; Florian B Cornely; Laura Knauth; Felix Köhler; Philipp Köhler; Carolin Krause; Christine Kronenberg; Sarah-Leonie Kranz; Vidya Menon; Hannah Müller; Jan-Hendrik Naendrup; Stefan Pützfeld; Anna Ronge; Jule Rutz; Danila Seidel; Hilmar Wisplinghoff; Oliver A Cornely
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-13       Impact factor: 3.267

Review 5.  Antifungal drug discovery through the study of invertebrate model hosts.

Authors:  R Pukkila-Worley; E Holson; F Wagner; E Mylonakis
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 6.  Management of invasive candidiasis in critically ill patients.

Authors:  Stijn Blot; Koenraad Vandewoude
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Clinical aspects of invasive candidiasis: endocarditis and other localized infections.

Authors:  Mario Venditti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

Authors:  Benoît P Guery; Maiken C Arendrup; Georg Auzinger; Elie Azoulay; Márcio Borges Sá; Elizabeth M Johnson; Eckhard Müller; Christian Putensen; Coleman Rotstein; Gabriele Sganga; Mario Venditti; Rafael Zaragoza Crespo; Bart Jan Kullberg
Journal:  Intensive Care Med       Date:  2008-10-30       Impact factor: 17.440

9.  Candidemia on presentation to the hospital: development and validation of a risk score.

Authors:  Andrew F Shorr; Ying P Tabak; Richard S Johannes; Xiaowu Sun; James Spalding; Marin H Kollef
Journal:  Crit Care       Date:  2009-09-29       Impact factor: 9.097

10.  Blood stream infections by Candida glabrata and Candida krusei: a single-center experience.

Authors:  Hee Kyoung Choi; Su Jin Jeong; Han Sung Lee; Bum Sik Chin; Suk Hoon Choi; Sang Hoon Han; Myung Soo Kim; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.